Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 1 25Phase 1/2 15Phase 3 6Phase 2/3 3Phase NA 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 5NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Gliosarcoma 2Spinal Cord Neoplasms 1Glioblastoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Temozolomide × Clear all
NCT02152982 2026-06-03

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

NCT01236560 2024-02-20

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

National Cancer Institute (NCI)

Phase 2/3 Completed
101 enrolled 15 charts
CNS

Astrocytoma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡